Titre

Profile of perampanel and its potential in the treatment of partial onset seizures

Type
synthèse (review)
Institution
Externe
Périodique
Auteur(s)
Rheims, S.
Auteure/Auteur
Ryvlin, P.
Auteure/Auteur
Liens vers les personnes
ISSN
1176-6328
Statut éditorial
Publié
Date de publication
2013
Volume
9
Première page
629
Dernière page/numéro d’article
37
Langue
anglais
Notes
Rheims, Sylvain
Ryvlin, Philippe
eng
New Zealand
Neuropsychiatr Dis Treat. 2013;9:629-37. doi: 10.2147/NDT.S30129. Epub 2013 May 13.
Résumé
Perampanel (PER) is a novel antiepileptic compound that decreases neuronal excitability by modulating glutamatergic transmission through selective noncompetitive blockade of AMPA receptors. PER has been evaluated in three pivotal placebo-controlled randomized trials as adjunctive therapy in adult drug-resistant partial epilepsy. In comparison to placebo, adjunctive PER effectively reduces seizure frequency. The relative risk of the responder rate (95% confidence interval [CI]) was thus 1.60 (1.08-2.36), 1.79 (1.42-2.25) and 1.66 (1.24-2.23) for once-daily PER 4 mg/day, 8 mg/day and 12 mg/day, respectively. The most common adverse events associated with PER were nonspecific central nervous system side effects. Some concerns have been raised about risk of clinically significant weight gain and of psychiatric adverse events. Long-term open-label extensions of the three pivotal trials are underway. PER has recently been approved both in Europe and in the USA for the adjunctive treatment of partial onset seizures in patients aged 12 years and above. However, in the absence of a direct comparison between PER and other licensed antiepileptic drugs' efficacy and tolerability, the clinical advantages of PER over the other drugs in intractable partial epilepsy remains to be determined.
Sujets

antiepileptic drug

epilepsy

partial seizures

perampanel

PID Serval
serval:BIB_502C706C67BB
DOI
PMID
Permalien
Open Access
Oui
Date de création
2018-11-29T11:37:06.897Z
Date de création dans IRIS
2025-05-20T19:53:17Z